Brian A. Markison, President and Chief Executive Officer, Nycomed US Inc.
David Klaum, Senior Vice President/General Manager, Fougera
A Generics Leader
Now in its 162nd year, Fougera® is the leading specialty pharmaceutical manufacturer and provider of high quality topical products. An eminent generics company since the advent of the industry in the 1960s, Fougera remains a principal player due to its forward-thinking technology and innovation, as well as its pipeline. Fougera credits its “Make No Compromises®” philosophy as the backbone of its success.
FDA Approval: Adapalene Cream 0.1% (Rx)
Fougera’s FDA approval of its Adapalene Cream 0.1% (Rx) included a rating of AB as generically equivalent to Differin® (Galderma) and indicated for the treatment of acne vulgaris.
Imiquimod Cream 5% (Rx)
Fougera’s FDA approval of its Imiquimod Cream 5% (Rx) included a rating of AB as generically equivalent to Aldara® (Graceway Pharmaceuticals). The product is available in single use foilpacs®, Fougera’s proprietary packaging innovation. “Fougera continues to develop cost-effective, safe, and effective generic treatment options for healthcare providers and patients. Receiving the first generic approval for Imiquimod Cream demonstrates our capabilities and commitment,” said David Klaum, Senior Vice President and General Manager. Fougera continues to receive topical FDA approvals—more than any other topical generic company—including a wide range of creams, ointments, gels, lotions, and solutions.
Founded by pharmacist Edmond Fougera in 1849, Fougera has a long tradition of serving pharmacists and healthcare providers. A wider audience of wholesalers and distributors, hospital, chain, and community pharmacy, medical, surgical, managed care, government, and export markets all rely on Fougera. The company prides itself on delivering on its promise to meet customer needs and anticipate emerging ones.
Generics Industry Update
Over 10,000 FDA-approved generic drugs are available. The IMS Institute for Healthcare Informatics report, titled The Use of Medicines in the United States Review of 2010, observed that generics fill 78% of all prescriptions dispensed in the Unites States, 4% higher than 2009. Fougera is proud to contribute to the role that generic manufacturers play in providing high quality, safe and effective treatments that reduce cost for consumers and the healthcare system.
The Fougera Organization and Its Pipeline
Fougera is the leading manufacturer and distributor of a wide range of topical products. With the establishment of our sister division PharmaDerm® in 2002, a specialty pharmaceutical company dedicated to developing and commercializing prescription products to treat diseases and conditions of the skin such as Solaraze®, Cutivate Lotion®, Oxistat®, and Veregen®, and Savage Laboratories®, featuring such brands as Surgilube® and Nitro-Bid®, we cover the overall scope for topical dermatology. From product conception, through design and quality manufacturing, to high quality service to our customers, all of our divisions work endlessly to ensure that we do the best to introduce and maintain the proper lifecycle for our complete product portfolio. Fougera is steadfast in its mission to deliver with its “Make No Compromises®” approach. PT
For more information, please visit www.fougera.com.
Imiquimod Cream 5% (Rx) is available in single-use foilpacs®, a Fougera® innovation.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs